Comprehensive Study Notes on Hypertension and Clinical Pharmacy and Management

Overview and Classification of Hypertension

  • Definition: Hypertension is defined as persistently elevated arterial blood pressure (BP).

  • Classification (2017 ACC/AHA Guidelines):

    • Normal: Systolic Blood Pressure (SBP) <120 mm Hg<120\,mm\,Hg AND Diastolic Blood Pressure (DBP) <80 mm Hg<80\,mm\,Hg.

    • Elevated: SBP 120−129 mm Hg120-129\,mm\,Hg AND DBP <80 mm Hg<80\,mm\,Hg.

    • Stage 1 Hypertension: SBP 130−139 mm Hg130-139\,mm\,Hg OR DBP 80−89 mm Hg80-89\,mm\,Hg.

    • Stage 2 Hypertension: SBP ≥140 mm Hg\ge140\,mm\,Hg OR DBP ≥90 mm Hg\ge90\,mm\,Hg.

  • Isolated Systolic Hypertension: Defined as DBP <80 mm Hg<80\,mm\,Hg and SBP ≥130 mm Hg\ge130\,mm\,Hg.

  • Hypertensive Crisis: Defined as BP >180/120 mm Hg>180/120\,mm\,Hg.

    • Hypertensive Emergency: Extreme BP elevation with acute or progressing end-organ damage.

    • Hypertensive Urgency: Extreme BP elevation without acute or progressing end-organ injury.

Pathophysiology and Clinical Presentation

  • Etiology:

    • Primary (Essential) Hypertension: Results from an unknown etiology. This accounts for the majority of cases.

    • Secondary Hypertension: Accounts for <10%<10\% of cases. Usually caused by a specific underlying condition such as chronic kidney disease (CKD) or renovascular disease.

  • Drug-Induced Hypertension: Specific medications that may increase BP include:

    • Corticosteroids

    • Estrogens

    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

    • Cyclosporine

    • Erythropoietin

    • Venlafaxine

  • End-Organ Damage (Main Complications):

    • Brain: Stroke.

    • Vision: Hypertensive retinopathy (Vision loss).

    • Heart: Heart attack (Myocardial Infarction).

    • Kidneys: Kidney failure.

    • Blood Vessels: Atherosclerosis (Blood vessel damage).

  • Clinical Presentation:

    • Patients with uncomplicated primary hypertension are usually asymptomatic initially.

    • Patients with secondary hypertension may exhibit symptoms of the underlying disorder.

  • Diagnosis: Elevated BP may be the only sign. Diagnosis should be based on the average of two or more readings taken at each of two or more clinical encounters.

Treatment Goals and Nonpharmacologic Therapy

  • Overall Goal: To reduce morbidity and mortality from cardiovascular (CV) events, cerebrovascular events, and renal failure.

  • Target Blood Pressure:

    • For most patients: <130/80 mm Hg<130/80\,mm\,Hg.

    • Institutionalized older patients or those with high disease burden/limited life expectancy: Consider a relaxed SBP goal of <150 mm Hg<150\,mm\,Hg (or <140 mm Hg<140\,mm\,Hg if tolerated).

  • Lifestyle Modifications (Nonpharmacologic):

    • Weight Loss: Indicated if overweight or obese.

    • DASH Eating Plan: Dietary Approaches to Stop Hypertension.

    • Reduced Salt Intake: Ideally to 1.5 g/day1.5\,g/day of sodium (equivalent to 3.8 g/day3.8\,g/day of sodium chloride).

    • Physical Activity: 90−150 minutes/week90-150\,minutes/week of aerobic or dynamic resistance training.

    • Moderation of Alcohol Intake.

    • Smoking Cessation: Does not directly control BP but reduces overall cardiovascular disease risk.

Pharmacologic Therapy: General Approach and First-Line Options

  • Initial Drug Selection:

    • Stage 1 Hypertension: Use a single first-line drug in most patients.

    • Stage 2 Hypertension: Start combination drug therapy, preferably with two first-line drugs.

  • First-Line Antihypertensive Classes:

    1. Angiotensin-Converting Enzyme (ACE) Inhibitors.

    2. Angiotensin II Receptor Blockers (ARBs).

    3. Calcium Channel Blockers (CCBs).

    4. Thiazide Diuretics.

  • Alternative Classes: β\beta-blockers, α1\alpha_1-blockers, direct renin inhibitors, central α2\alpha_2-agonists, and direct arterial vasodilators are used in select patients or after first-line agents.

Compelling Indications for Specific Drug Classes

  • Heart Failure with Reduced Ejection Fraction (HFrEF):

    • Standard first-line: ACEi or ARB, then add specific β\beta-blockers (bisoprolol, carvedilol, or metoprolol succinate).

    • Add diuretic if edema is present.

    • Add-on: Mineralocorticoid receptor antagonist (MRA).

  • Heart Failure with Preserved Ejection Fraction (HFpEF):

    • Standard: ACEi, ARB, or β\beta-blocker. Diuretic if edema is present.

  • Stable Ischemic Heart Disease (SIHD):

    • First-line: β\beta-blockers (without Intrinsic Sympathomimetic Activity [ISA]).

    • Add ACEi or ARB.

    • Add CCB if angina persists; Thiazide as add-on if needed.

  • Diabetes Mellitus:

    • Without albuminuria: Any first-line agent (ACEi, ARB, CCB, or Thiazide).

    • With albuminuria: Treat like CKD (ACEi or ARB titrated to maximum tolerated dose).

  • Chronic Kidney Disease (CKD):

    • First-line: ACEi or ARB.

  • Secondary Stroke Prevention:

    • Thiazide, ACEi, or ARB, or Thiazide with ACEi.

Detailed Pharmacology of Drug Classes

Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Agents: Captopril, enalapril, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, and trandolapril.

  • Mechanism: Block conversion of angiotensin I to angiotensin II (a potent vasoconstrictor and stimulator of aldosterone).

  • Monitoring and Side Effects:

    • Acute Kidney Injury (AKI): Preexisting kidney disease or renal artery stenosis (bilateral or unilateral) increases risk.

    • Hyperkalemia: Due to decreased aldosterone. Common in CKD or those on potassium supplements.

    • Serum Creatinine: Modest increases (<1 mg/dL<1\,mg/dL) are acceptable.

    • Dry Cough: Occurs in up to 20%20\% of patients due to inhibition of bradykinin breakdown.

    • Angioedema: Occurs in <1%<1\%; requires immediate withdrawal.

    • Contraindication: Pregnancy.

Angiotensin II Receptor Blockers (ARBs)
  • Agents: Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.

  • Mechanism: Directly block the angiotensin II type 1 receptor.

  • Side Effects: Similar to ACEi (renal insufficiency, hyperkalemia) but no cough because they do not affect bradykinin.

  • Contraindication: Pregnancy.

Calcium Channel Blockers (CCBs)
  • Dihydropyridines (DHP): e.g., Amlodipine, Nifedipine, Felodipine.

    • May cause reflex sympathetic activation (increased heart rate) and peripheral edema.

    • Amlodipine and Felodipine have minimal negative inotropic effects.

    • Side effects: Dizziness, flushing, headache, gingival hyperplasia.

  • Non-Dihydropyridines (Non-DHP): Verapamil and Diltiazem.

    • Negative inotropic effects; Verapamil can precipitate HF in borderline patients.

    • Verapamil side effect: Constipation (7%7\%).

    • Diltiazem decreases heart rate less than verapamil.

Diuretics
  • Thiazides: Preferred first-line. Chlorthalidone is preferred over hydrochlorothiazide because it is more potent.

    • Side effects: Hypokalemia, hypomagnesemia, hypercalcemia, hyperuricemia, hyperglycemia, dyslipidemia, sexual dysfunction.

  • Loop Diuretics: Furosemide, Bumetanide, Torasemide.

    • More potent for diuresis; preferred in severe CKD (eGFR <30 mL/min/1.73 m2<30\,mL/min/1.73\,m^2) or if edema is present.

    • Side effects: Hypokalemia, hypocalcemia.

  • Potassium-Sparing Diuretics: Weak antihypertensives alone; used to counteract potassium wasting.

  • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone and Eplerenone.

    • Used in resistant hypertension and HFrEF.

    • Side effect: Spironolactone causes gynecomastia in up to 10%10\% of patients.

β\beta-Blockers
  • Usage: Reserved for compelling indications (Angina, HF, MI).

  • Cardioselective (β1\beta_1-selective): Atenolol, betaxolol, bisoprolol, metoprolol, and nebivolol. Safer in asthma/diabetes at low doses.

  • Intrinsic Sympathomimetic Activity (ISA): Acebutolol, carteolol, pindolol. Do not reduce CV events and may increase risk in SIHD.

  • Side Effects: Bradycardia, AV conduction abnormalities, acute HF, cold extremities (blocking β2\beta_2). Avoid abrupt cessation; taper over 1−2 weeks1-2\,weeks.

Other Agents
  • α1\alpha_1-Receptor Blockers: Prazosin, terazosin, doxazosin. Used for BPH; only used for BP as add-on therapy.

  • Direct Renin Inhibitor: Aliskiren. Limited role.

  • Central α2\alpha_2-Agonists: Clonidine (resistant hypertension), Methyldopa (pregnancy-induced hypertension).

  • Direct Arterial Vasodilators: Hydralazine, Minoxidil. Directly relax arteriolar smooth muscle.

Special Populations

  • Older Persons: Correlate CV risk more with SBP. Start with lower-than-usual initial doses.

  • Children/Adolescents: Secondary hypertension is more common. Nonpharmacologic treatment is the cornerstone.

  • Pregnancy:

    • Preeclampsia: Definitive treatment is delivery. Labor induction if eclampsia (convulsions) is imminent.

    • Acute/Severe BP in Pregnancy: Target DBP 95−105 mm Hg95-105\,mm\,Hg. Use IV hydralazine or IV labetalol.

    • Chronic Hypertension in Pregnancy: First-line: Labetalol, long-acting nifedipine, or methyldopa.

    • Contraindications: ACEi, ARBs, Aliskiren, and Valsartan/Sacubitril.

  • Black Patients: CCBs and Thiazides are most effective as first-line therapy.

  • Pulmonary/PAD: Cardioselective β\beta-blockers are safe in asthma/COPD. β\beta-blockers do not worsen claudication in Peripheral Arterial Disease.

Hypertensive Emergencies and Urgencies Management

  • Urgency: Short-acting oral drugs (captopril, clonidine, or labetalol) are options.

  • Emergency: Requires immediate BP reduction with parenteral (IV) agents to limit end-organ damage. IV labetalol is used commonly.

Questions & Discussion

  • Q36: Hypertension of 180/120 mm Hg180/120\,mm\,Hg resulting in renal failure is classified as Hypertensive emergency.

  • Q37: The modifiable risk factor for coronary artery disease is Obesity.

  • Q15: Useful for treating orthostatic hypotension: Fludrocortisone.

  • Q16: Stage requiring combination drug therapy as initial regimen: Stage 2 hypertension.

  • Q33: FDA approved β\beta-blocker for HFrEF: Bisoprolol (others are carvedilol, metoprolol succinate).

  • Q34: First-line for SIHD: Beta-blockers (without ISA).

  • Q101: Preferred agent for hypertensive patient with T2DM and NO albuminuria: Any first-line agents can be used.

  • Q89: Drug reducing intraglomerular pressure in CKD: ACE inhibitors.

  • Q103: Serious side effect in hypertension with CKD: ACE inhibitors can cause AKI.

  • Q72: ACEi are contraindicated in: Renal artery stenosis.

  • Q20: Contraindicated during pregnancy: Enalapril (ACEi).

  • Q100: Medication causing gingival hyperplasia: Nifedipine.

  • Q27: Diuretic causing low K (3.3 mEq/L3.3\,mEq/L) and high Ca (10.3 mg/dL10.3\,mg/dL): Chlorthalidone.

  • Q50: Not a side effect of spironolactone: Visual disturbances (gynecomastia, impotence, hyperkalemia, and menstrual irregularities are side effects).

  • Q96: Best treatment for HTN in pregnancy or while trying to conceive: Discontinue lisinopril and start labetalol.

  • Q67: Antihypertensive helping osteoporosis in addition to BP: Thiazide diuretic (e.g., Hydrochlorothiazide) due to hypercalcemic effect.

  • Q64: End-organ damage occurs primarily in: Heart and brain (and eyes, kidneys, vasculature).